Investing Profile

Michael Aberman

InvestorVC
General Partner at Regeneron Ventures
Photo of Michael Aberman, General Partner at Regeneron Ventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
The Wharton School Network
841 CONNECTIONS
Morgan Stanley Network
707 CONNECTIONS
Cornell University Network
391 CONNECTIONS
Credit Suisse Network
322 CONNECTIONS
My Perfect Sale (acquired by Sugar, Inc) Network
176 CONNECTIONS
cb
Regeneron Ventures General Partner
$100K - $2.0M
$1M
1

Sign in to see all 1 investments on record.

Sign in with Google →
General Partner Regeneron VenturesPresent
General Partner My Perfect Sale (acquired by Sugar, Inc)Present
President and CEO Quentis Therapeutics, IncPresent
President and CEO My Perfect Sale (acquired by Sugar, Inc)Present
Board Member XenImmune Therapeutics, Inc.Present
Board Member My Perfect Sale (acquired by Sugar, Inc)Present
Business Advisor Excision BioTherapeuticsPresent
Board Member Unnatural ProductsPresent
Board Member Unnatural Products Inc.Present
SeniorAdvisor ImmunaiPresent
Board Member Rover DiagnosticsPresent
Senior Vice President, Strategy and Investor Relations RegeneronPresent
Biotech Analyst Credit SuissePresent
Biotech Analyst Morgan StanleyPresent
Senior Director, Business Development AntigenicsPresent
Resident NewYork-Presbyterian HospitalPresent
General Partner Quentis Therapeutics, IncPresent
Board Member Quentis Therapeutics, IncPresent
General Partner CnationPresent
President and CEO CnationPresent
Board Member CnationPresent
Cornell University BA Biology
University of Toronto MD Medicine
The Wharton School MBA Healthcare
Sign in with Google →
Sign in with Google →